Pharma Pipeline Health
200 industry sponsors, 22,653 trials (Phase 1-4, 2015+) Updated: 3/29/2026
9,679
Phase 1
Early innovation
5,999
Phase 2
Efficacy testing
5,866
Phase 3
Near approval
1,109
Phase 4
Post-market
200
Industry
Pharma sponsors
Industry sponsors only (normalized names)
| Company | Ph1 | Ph2 | Ph3 | Ph4 | Score | Status |
|---|---|---|---|---|---|---|
| AstraZeneca | 508 | 264 | 321 | 65 | 5,611 | 183R 625C 115F |
| Novartis | 220 | 357 | 299 | 99 | 5,314 | 127R 462C 216F |
| Pfizer | 499 | 206 | 195 | 53 | 4,031 | 95R 589C 166F |
| Eli Lilly | 488 | 146 | 223 | 33 | 3,969 | 125R 584C 75F |
| Bristol-Myers Squibb | 427 | 220 | 159 | 23 | 3,567 | 88R 472C 120F |
+ 195 more companies
Upgrade to Pro for full pipeline analysis across 200 pharma companies
See Pro FeaturesScore: (Ph3 × 10) + (Ph2 × 5) + (Ph1 × 2) + (Ph4 × 1) — weights near-term approvals highest
Status: R = Recruiting, C = Completed, F = Failed (Terminated/Withdrawn/Suspended)
Source: ClinicalTrials.gov